Imai, Takeharu http://orcid.org/0000-0003-2174-7392
Tanaka, Yoshihiro
Hatanaka, Yuji
Suetsugu, Tomonari
Sato, Yuta
Matsuhashi, Nobuhisa
Tsunekawa, Koji
Saiki, Takuya
Yoshida, Kazuhiro
Article History
Received: 16 September 2021
Accepted: 23 November 2021
First Online: 29 January 2022
Declarations
:
: Dr. Yoshida reports grants and lecture fees from Asahi Kasei Pharma, Chugai Pharma, Covidien Japan, Daiichi Sankyo, Eli Lilly Japan, Johnson & Johnson, MerkSerono, MSD, Nippon Kayaku, Novartis Pharma, Ono Pharm., Otsuka Pharm., Sanofi, Taiho Pharm., Takeda Pharm., TERUMO, Tsumura & Co., akult Honsha; grants from Abbott, Abbvie, Astellas, Biogen Japan, Celgene, Eisai, EPâCRSU, EPS Corporation, FUJIFILM, GlaxoSmithKline K.K., Kaken Pharm., Kyowa Kirin, Meiji Seika Pharma, Philips, Toray Medical; lecture fees from AstraZeneka, Bristol-Myers Squibb Japan, Denka Co., Ltd, EA Pharma, Olympus, Pfizer, Sanwa Kagaku Kenkyusho, SBI Pharma, Teijin Phamra, outside the submitted work. The other authors have no conflicts of interest to disclose.
: Before each medical student participated as a subject in the research, the research coordinator explained the process in detail using explanatory documents, and then obtained their voluntary consent after confirming their understanding. All images were created from data from one patient with esophageal cancer, who consented to the use of their data for this study after the process was explained using explanatory documents. Personal information in this research was managed in compliance with the research plan as per ethical guidelines for medical research for humans and the applicable laws and regulations.